Background: Currently, very few studies exist regarding the use of systemic methotrexate (MTX) in childhood psoriasis.
INTRODUCTION
P soriasis is a chronic, inflammatory condition of the skin having prevalence rates between 1% and 3% in the general population. [1, 2] Every year approximately 20,000 children younger than 10 years of age are diagnosed with psoriasis, with an overall prevalence of pediatric psoriasis estimated at 1-2%. [3] There is varied spectrum of childhood psoriasis-like guttate, plaque, intertriginous variants to severe forms such as pustular and erythrodermic psoriasis described in the literature. Various management options such as topical treatments, photo (chemo) therapy, conventional systemic treatments, and biologics are available for treatment of psoriasis. Although most of the childhood psoriasis patients can be managed with topical therapy alone those presenting with severe disease and not responding to topical need systemic treatment. Among systemic treatment modalities methotrexate (MTX) is regarded as the therapy of choice and has been used in the treatment of childhood psoriasis by various workers. [6] [7] [8] 
MATERIALS AND METHODS
All the patients <18 years of age with severe psoriasis not responding to topical therapy, with psoriasis area severity index (PASI) >10 and having no contraindication to systemic MTX use were included in the study done during a period of two years. Those children with active infection and having any other contraindication to MTX were excluded from the study. Diagnosis of various patterns of psoriasis was made clinically and was confirmed by histopathology. Detail demographic characteristics, duration of disease, body surface area involved, and morphological type of psoriasis were recorded [ . Those patients fulfilling the inclusion criteria were prescribed systemic MTX. MTX was administered orally at a dose of 0.2-0.4 mg/kg/week and folic acid was prescribed on a daily basis except on the day of MTX intake to ameliorate side effects and toxicity of MTX. The response to MTX was measured objectively by recording the value of PASI in each visit. The treatment was continued till 75% improvement in PASI and after that dose was decreased at a rate of 2.5 mg/week and stopped after complete cure of disease. Those patients who showed an increase in PASI by 50% of the last dose of MTX after complete stoppage of therapy were considered to have relapse and were restarted with MTX. Response to therapy was graded as good (50-75% decrease in PASI) and excellent (>75% decrease). The patients were followed up weekly for the first 2 weeks and then at 15 days interval for 1 month and monthly after that for measuring improvement in PASI and to rule out any side effects of MTX clinically and by laboratory monitoring. Baseline laboratory investigations such as complete blood count, liver function tests, renal function tests, chest X-ray, serological tests for hepatitis B and HIV was carried out in all cases before the commencement of systemic MTX therapy as well as in follow-up visits. An appropriate Institutional Review Board had approved the project before starting the study and informed consent was appropriately obtained from parents of the patients before enrolling them for the study.
RESULTS
Totally 9 patients were included in the study within 2 years of the study of which 6 were male and 3 were female [ Table 1 ]. Mean age was 12.78 ± 1.9 years. The mean duration of onset disease was 7.2 ± 3.7 months. Of 9, 4 had chronic plaque psoriasis, 1 had erythrodermic psoriasis, whereas rupoid and pustular psoriasis constituted two patients each. Mean BSA involvement and mean baseline PASI were 64.0 ± 1.71% and 29.7 ± 9.5, respectively. All patients responded dramatically to oral MTX except the patients of rupoid psoriasis who took longer time to achieve 75% improvement in PASI.
The mean duration required to achieve 50% and 75% improvement in PASI overall were 4.6 ± 2.46 weeks and 7.6 ± 3.36 weeks, respectively. The total duration of treatment to achieve complete clearance of disease was 8.8 ± 3.83 months. Out of nine patients, six patients are continuing 2.5 mg of MTX per week now and rest three cases of pustular, erythrodermic and chronic plaque psoriasis are off from the drug since 3, 5, and 6 months, respectively and are being followed up. The total cumulative dose of MTX in all cases to till present is 231.1 ± 176.1 mg [Tables 2 and 3] . No major side effects and derangement in laboratory parameters were noted in any patients except nausea and vomiting in two cases. Scalp involvement was found in cases of rupoid and chronic plaque psoriasis. Nail examination revealed nail plate thinning and few pits in two cases.
DISCUSSION
Psoriasis in children in generally managed with topical treatments, but systemic treatment is required in these patients with severe plaque psoriasis and life-threatening variants such as pustular, rupoid, and erythrodermic psoriasis. Childhood psoriasis adds significant psychosocial morbidity. There are many reports of childhood psoriasis being managed with drugs such as ciclosporin, retinoids, MTX, and biologicals. Recently, in a few studies by Collin et al., [7] Kaur et al., [8] systemic MTX has been proved to be an effective agent in managing childhood psoriasis.
MTX inhibits the enzymes dihydrofolate reductase and thymidylate synthase, as well as other enzymes involved in de novo purine synthesis. In this way, they deplete the intracellular reserve of fully reduced folates, and thus affect transmethylation reactions inhibition of thymidylate synthesis is the most important effect exerted by MTX, which results in DNA synthesis, thus inhibiting replication and function of T and B lymphocytes also interferes with epidermal cell kinetics. [9] In addition, MTX decreases DNA synthesis and induces apoptosis in keratinocytes. [10, 11] MTX acts by various mechanisms in psoriasis mostly target the immune system, i.e. aberrant T-cell response. [12] It impairs complement C5a-induced skin response and leukotriene B4-induced intraepidermal penetration of granulocytes. [13] Recently, it has been found that MTX significantly reduces serum levels of interleukin-22, a cytokine that promotes keratinocyte proliferation and dermal inflammation in psoriasis. [14] MTX also acts through a reduction in the mRNA levels of peroxisome proliferator-activated receptor b/δ, a member of the nuclear hormone receptor superfamily that contributes to psoriasis pathogenesis. [15] Also by inhibiting 5-aminoimidazole-4 carboxamide ribonucleoside transformylase, MTX induces the release of adenosine, which inhibits generation of oxygen free radicals by polymorphonuclear cells (PMNs), adhesion of PMNs, macrophage-induced modulation of tumor necrosis factor-α, and proliferation of lymphocytes, thereby playing a role of anti-inflammatory and immune modulatory agent in psoriasis. [16] Currently, there are no guidelines for use of MTX in childhood psoriasis although it has been extensively studied in the case of adults. Knowing all the adverse effects, it should be always used as a reserve drug in psoriasis not responding to topical treatments and severe form of psoriasis such as pustular, erythrodermic variants as well as recalcitrant chronic plaque psoriasis. In a few studies conducted on efficacy and safety of systemic MTX in childhood psoriasis, no side effects were observed, and it was proved to be a safer drug if monitored properly. However, the side effects such as bone marrow suppression, liver fibrosis could not be underestimated in case of long-term use of MTX and it should be always used to control the disease rather than a cure option and should be stopped after achieving 75% improvement in PASI and to be restarted in case of flare up of disease as psoriasis itself decreases in severity in summer and flares up in winter.
Although there are other drugs such as retinoids, cyclosporine, hydroxyurea, biologicals, and PUVA therapy available safety profile, long-term use and cost are constraints to use them in childhood psoriasis. [17] Retinoids have an effect on bone growth, cyclosporine being a reno-toxic drug could not be used for long-term. [18, 19] The experience of hydroxyurea and biological is limited. [20, 21] Hence, larger number of studies are required to weigh the risk-benefit ratio of use of such drugs in case of children having psoriasis.
In our study also the response to systemic MTX was dramatic, and safety profile was good without any major side effects. Most of the patients achieved clearance in 8.8 months, and the mean duration required to achieve 50% and 75% improvement in PASI overall were 4.6 ± 2.46 weeks and7.6 ± 3.36 months respectively with very few gastrointestinal (GI) side effects.
Except in the case of rupoid psoriasis, improvement was quick in all cases. In two cases MTX has been stopped, and they are now in follow-up and in rest 5 cases are in 2.5 mg/week of MTX along with folic acid 5 mg. Hence, we conclude that systemic MTX can be considered as a safer treatment option in severe refractory cases of childhood psoriasis if proper monitoring and follow-up is done.
Limitation
However, limitations of our study were small sample size, absence of investigations to rule out liver toxicities III procollagen amino-terminal propeptide level and liver biopsy CONCLUSION MTX is a safe therapeutic option in severe refractory cases of childhood psoriasis and can be used as a safe option with mean duration required to achieve 50% and 75% improvement in PASI overall were 4.6 ± 2.46 weeks and 7.6 ± 3.36 months with very few GI side effects.
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